{Reference Type}: Journal Article
{Title}: COVID-19 among lung cancer patients: Data from a real-life prospective French multicentric study.
{Author}: Olivier M;Julian P;Acya BT;Sophie S;Benoît G;Laurent P;Hugues F;Charles D;Julie O;Cécile D;Patrick D;Sylvie J;Nicolas M;Alexia L;Hugues M;Didier D; ;
{Journal}: Respir Med Res
{Volume}: 86
{Issue}: 0
{Year}: 2024 Mar 4
{Factor}: 3.149
{DOI}: 10.1016/j.resmer.2024.101093
{Abstract}: <B>BACKGROUND: </B>COVID-19 started to spread early in 2020, the precise year that lung cancer (LC) patients were recruited into the prospective epidemiological cohort KBP-2020-CPHG in French hospitals. This provides a unique opportunity to study COVID-19 incidence, survival risk factors, and overall prognosis.<BR><B>METHODS: </B>COVID data was collected before vaccination was made available. Clinical characteristics were compared (COVID vs non-COVID), incidence rate ratios were calculated based on clinical characteristics, survival (1 and 3 months) was estimated and the impact of COVID-19 on the overall prognosis of the cohort was studied.<BR><B>RESULTS: </B>In 2020, 285 out of 8,999 lung cancer patients were diagnosed with COVID-19. Diagnosis was mainly based on PCR tests (86.3 %). The annual incidence was 8.3 % (95 % CI [7.4, 9.3]); it was higher in former smokers and patients with squamous cell carcinoma or small cell carcinoma than in those with adenocarcinoma, in those with a PS score ≥2 versus 0-1, and with stages III-IV versus stages I-II. The incidence was reduced in patients who received chemotherapy or immunotherapy. 64.9 % of patients were hospitalized due to COVID-19. Risk factors for death at 1 and 3 months in COVID-19 patients were age, LC stage, and PS score. Multivariate analysis showed a major prognostic impact of COVID-19 on mortality of LC patients (hazard ratio: 4.12, 95 % CI [3.42, 4.97], p < 0.001).<BR><B>CONCLUSIONS: </B>This prospective study demonstrated the high incidence of COVID-19 in LC patients and identified as risk factors for COVID-19: smoking status, histology, PS, and stage. The impact of COVID-19 on lung cancer mortality appears major.